These tumors are not increasing in incidence as quickly as other melanomas, but they are associated with worse prognosis.
Acral lentiginous melanoma (ALM) accounts for 2% to 3% of all melanomas; however, many studies of this lesion have been small series from single institutions rather than nationwide surveys of clinical patterns. Bradford and colleagues recently examined ALMs using data from the NCI SEER registry. Between 1986 and 2005, the overall age-adjusted incidence rate of ALM was 1.8 per 1,000,000 person-years. By contrast, the per–1,000,000-person-year incidence rates of the other major melanoma histologic subtypes were lentigo-maligna melanoma, 12.0; nodular melanoma (NM), 12.7; and superficial spreading melanoma (SSM), 57.4. Thus, new ALMs occur roughly 1/50th as often as SSMs. ALM incidence increased from 1.6 per 1,000,000 person-years in 1992–1994…
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)